研究单位：[1]The First Affiliated Hospital of Nanchang University[2]Hangzhou Grand Biologic Pharmaceutical, Inc.[3]The First People's Hospital of Yunnan[4]Zhejiang Provincial Hospital of TCM[5]Fifth Affiliated Hospital of Zhengzhou University[6]Nanjing First Hospital, Nanjing Medical University[7]Xi'an Central Hospital[8]The First Affiliated Hospital of Shanxi Medical University[9]Renmin Hospital of Wuhan University[10]The First Affiliated Hospital of Nanchang University,Nanchang,Jiangxi,China[11]Xi'an Central Hospital,Xi'an,Shanxi,China
研究目的：
The purpose of this clinical trial is to evaluate the clinical efficacy of Bifidobacterium quadruple live bacteria tablets (Si Lian Kang) on reducing the incidence rate of adverse reactions of Helicobacter pylori quadruple eradication therapy and its influence on gastrointestinal flora.
